Taysha Gene Therapies has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $150,000,000.00 in Post-IPO Equity.
According to filings with the U.S. Securities and Exchange Commission, Taysha Gene Therapies is raising $150,000,000.00 in new funding. About Taysha Gene Therapies: Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
To learn more about Taysha Gene Therapies, visit http://tayshagtx.com/
Contact:
Sean Nolan, Chief Executive Officer
214-612-0000
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.